Shionogi launches severe thrombocytopenia treatment drug Mulpleo®
Category: #health  By Pankaj Singh  Date: 2020-03-09
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Shionogi launches severe thrombocytopenia treatment drug Mulpleo®

Chronic liver disease is a critical healthcare issue in the UK, with number of deaths recorded to go up by 400% since 1970. Currently, transfusion of platelets appears to be the only treatment option available to manage platelet counts, however, pharma institutes are constantly working on developing a new, viable treatment alternative.

Reportedly, Japanese pharmaceutical company, Shionogi & Co. Ltd. and its European branch, Shionogi B.V., have recently made a striding development by launching Mulpleo® (lusutrombopag), a drug formulated to treat severe thrombocytopenia in adults suffering from chronic liver disease (CLD) and undergoing invasive procedures, in the UK.

Reportedly, Mulpleo® is the first-ever licensed treatment available on the UK’s NHS to treat this disorder. It has also bagged approval for funding across various health services in Scotland, Northern Ireland, and England & Wales.

According to reliable sources, the launch and approval of Mulpleo® were based on the findings derived from L-PLUS 2 and L-PLUS 1. Both these phase III studies are randomized, multicenter, parallel-group, double-blind, placebo-controlled for 312 CLD patients with <50,000/µL platelet count severe thrombocytopenia.

Speaking on the move, Dr. Andrew Holt, Consultant Physician (Liver, GI & HPB) at University Hospitals, Birmingham, said that the launch of Mulpleo comes as a piece of great news for CLD patients, as it bags approval from both NICE and SMC. Over the years, there has been a significant rise in patients suffering from chronic liver disease and this trend is expected to continue in the future.

To this date, doctors and CLD patients did not have any specific therapies for curing thrombocytopenia, a common complication of chronic liver disease which could delay or obscure vital interventions for CLD patients. Evidently, with the introduction of Mulpleo, physicians can now harness a valuable tool for safely facilitating these interventions, added Dr. Holt.

Source Credit: https://finance.yahoo.com/news/shionogi-announces-launch-mulpleo-lusutrombopag-000100194.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Nanjing Bioheng Biotech obtains ODD from US FDA for treating T-ALL

Nanjing Bioheng Biotech obtains ODD from US FDA for treating T-ALL

By Pankaj Singh

Bioheng Biotech Co. Ltd. has reportedly announced that its CD7-targeting T-cell therapy product, code CTD401, has obtained the Orphan Drug Designation (ODD) from the US FDA for treating T-cell acute lymphoblastic leuke...

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

Tiziana to initiate development of ‘Take Home’ nasal COVID treatment

By Pankaj Singh

Biotechnology company, Tiziana Life Sciences plc, has reportedly announced the submission of a grant to the UK-CTAP (United Kingdom COVID Therapeutics Advisory Panel).

This ...

IKEA set to deliver its home furnishing products in Bengaluru

IKEA set to deliver its home furnishing products in Bengaluru

By Pankaj Singh

Retail furniture company IKEA has reportedly declared that it is set to deliver its wide product range of home furnishing in Bengaluru.

IKEA has a variety of home furnishing product...